Italy-headquartered blood products specialist Kedrion Biopharma has announced that its subsidiary, Bio Products Laboratory (BPL), has received approval from China’s National Institutes for Food and Drug Control (NIFDC) to release human albumin into the Chinese market for the first time. This milestone follows a 2022 partnership established between Kedrion and BPL to supply human albumin to China, further solidifying their presence in the world’s largest albumin market.
Partnership and Distribution in China
Kedrion and BPL have also partnered with Hangzhou Jiansheng Medicine Co., Ltd for the distribution of the product within China. This strategic collaboration aims to enhance the accessibility of human albumin to Chinese patients, addressing the country’s reliance on imports for maintaining albumin supplies.
Background on Kedrion and BPL Merger
The approval from NIFDC comes after Kedrion merged with BPL in September 2022, following an investment from private equity firm Permira Funds. Since 2016, BPL, a UK-based company, had been owned by China-based Creat Group Corporation, which invested GBP 100 million. The NIFDC’s approval to launch human albumin into the market follows the official approval from the National Medical Products Administration (NMPA) issued in January 2021 for BPL’s Albuminex 25% (human albumin) product.-Fineline Info & Tech
